

A Meeting of the **Borders Area Drugs and Therapeutics Committee** held at 12:30pm on
Wednesday, 28 JANUARY 2026 via Microsoft Teams



MINUTE

Item	Situation; Background; Assessment	Recommendation	Lead
1.	<p>Welcome and Announcements: Malcolm Clubb, Director of Pharmacy (MC) (CHAIR) welcomed those present at the meeting and noted apologies. Dr Nicola Henderson, GP (NH); Dr Edward James, Consultant Microbiologist (EJ); Rhona Morrison, Medicines Governance and Non-Medical Prescribing Lead (RM); Kyna Harvey, Lead Clinical Pharmacist (KH); Keith Maclure, Lead Pharmacist – Medicines Utilization & Planning (KMacl); Kate Warner, Meeting Administrator (KW). Apologies: Andrew Leitch, Lay-member Dr Sohail Bhatti, Director of Public Health; Dr Rebecca Devine, Public Health Consultant; Dr Effie Dearden, Consultant DME.</p>		
1.1	<p>Declarations of Interest:</p>		
2.	<p>DRAFT Minute previous meeting</p>		
2.1	<p>Draft minute from 26 November 2025 meeting was approved as an accurate record of the meeting with no changes. Thank you to NH for chairing the November 2025 meeting.</p>	<p>Remove draft, save and upload web.</p>	<p>KW 28/01/2026</p>
3.	<p>Matters Arising</p>		
3.1	<p>Single Nurse Administration of Injectable Medicines in Community Hospital Clinical Areas Right Decisions has been added as a GUIDELINE Page. Version 1.0; Reviewer – Morrison, R; Expiry date 30/11/2028. Approved at November meeting with changes.</p>	<p>ADTC Noted</p>	
3.2	<p>ADTC reviewed the updated Emergency MAR Chart; following recommendations made by ADTC at previous meeting. The chart is important for high-flow wards, Hospital at Home, Frailty Unit to give guidance and ownership and to ensure staff and support carers are aware of this. The chart would be handwritten with a prescription and supporting discharge; along with a change sheet for clinician to support carer administer medication. Medicines always have to be labelled. ADTC asked if this could be produced on controlled stationery; and can it be reduced to two pages not three to fit onto two sides (or four page booklet if more medications are to be added). The possibility of multiple MAR charts was discussed; this needs bold direction for carers to ensure that there should only be one MAR chart. Request to add to risk register to ensure that the risk is recognised of double charts. Request to score off “if immediate or complete a change form” as cannot ask carer to act on change form – this needs to be really clear. ADTC requested that changes be made and additional review of this chart, including C</p>	<p>ADTC requested changes to be made and it to return to ADTC. Discuss with C Proudfoot in further review.</p>	<p>RM MC and KH</p>

	Proudfoot in review. To be brought back to ADTC for approval.		
4.	NEW MEDICINE APPLICATIONS / NON-FORMULARY REQUESTS:		
4.1	NFR Panel decisions – spreadsheet including any feedback.	ADTC Noted	
5.	PATIENT & MEDICINES SAFETY:		
5.1	Patient and Medicines Safety Update - InPhase reports and Adverse Events results. A number of CD and desirable cabinet discrepancies reported. Data analyst is reviewing the data and will report back on medications. Dihydrocodeine was included and ADTC asked why this is in cabinet when it is not included in formulary; this will be reviewed. Policy on management has been requested of Pain team; check guidance has gone through organisational change. It was agreed that now cabinets are in place issues will be highlighted and ADTC require context for variants. Request to review this at March meeting.	ADTC Noted Add to March ADTC Review inclusion of dihydrocodeine in cabinets.	RM/KW RM
6.	CLINICAL POLICIES, PROCEDURES and GUIDELINES for APPROVAL:		
6.1	ADTC reviewed the SBAR - New Antibiotic approvals: Ceftazidime/Avibactam. Local approval is required for access to these two antibiotics; assessment was included from Dr Duguid. Currently 1-2 patients per annum but there is a national increase, and the request is to keep a supply in BGH Pharmacy. ADTC agreed that a monitoring strategy was required which would be Omnicell reports through to Antimicrobial Management Team. Also required discussion on how this is managed with locums. ADTC approved ordering and holding supply and requested a report on number of times used and indications viable.	ADTC Approved Email author with decision and report request: AD	KW 02/02/2026
6.2	ADTC reviewed the Arthroplasty Analgesia Pathway; national guidance for long-acting oxycodone – post-operative; using Oxycodone IR, not MR. The switch has commenced and there have been no issues. This is a solution to stopping using sustained release opiates post-operatives. Flow chart is included for management. Drug change as well as relief mechanism was discussed. Contra-indications, for example chronic kidney disease, discussed and it was agreed creatine clearance should be more specific. ADTC approved the guidance with the following updates - that the brand names be removed from the guidance; that creatine clearance be more specific and that the document be put into RDS template. Review and approval process was noted and ADTC agreed that it can be uploaded to RDS when changes are made.	ADTC Approved with changes as noted Email to author: SS Updated document to RDS template and upload	RM / KW 02/02/2026 KW 26/02/2026
6.3	ADTC reviewed the Paediatric PCA (Patient Controlled Analgesia) Pathway (cover page, guideline, pathway and prescription document). It was highlighted that this has been produced first for paediatric nurses as they are more familiar with PCAs and have received training. There are fewer patients; nurses more familiar and a smaller cohort of staff. The change of process is not as new as it is to adult services. This is an update to a previously approved policy. ADTC approved and requested this be put into RDS template. They requested that the adult PCA pathway should be tabled at the March meeting of ADTC.	ADTC Approved Email to author: SS Document to RDS template and upload. Invite SS to March ADTC with Adult PCA	KW 02/02/2026 KW 26/02/2026 MC 02/02/2026
6.4	ADTC reviewed the updated NHS Borders Drugs & Therapeutics Industry Engagement Policy which included tracked changes and comments. ADTC noted that p5 – products being considered – do not specify what is involved. Updated links to new national guidance. Wound Formulary meeting is required.	ADTC requested changes noted. Email to author:	KW

	ADTC agreed that changes should be made to the policy and then a final version come to ADTC virtually for approval. This will be updated in RDS and communications to be sent as reminders to appropriate staff.	KMacl / RM Updated version to be approved virtually	02/02/2026 ADTC 26/02/2026
6.5	ADTC reviewed the Elective Surgery Guideline and Pro-forma form update which has been approved by Anti-Coagulation Committee. ADTC heard that this had previously been Endoscopy Guideline for bleeding risk but required advice on mechanical valves. This has been updated for use by all – not just Endoscopy including updates to Enoxaparin. ADTC approved.	ADTC Approved Email to author: KH	KW 02/02/2026
6.6	ADTC reviewed the Guidance for Extended Venous Thromboembolism (VTE) Prophylaxis for Surgical Patients undergoing Major Abdominal or Pelvic Surgery for Cancer in NHS Borders which has been approved by Anti-Coagulation Committee. Includes Dalteparin to Enoxaparin and mechanical valves updates. ADTC discussed inpatient anti-coagulation. 14 days maximum – it is review not stop; default stop or new risk assessment at 14 days to avoid hard stop. ADTC requested that Anti-coagulation Committee approve after update and it can then come back to ADTC for virtual approval.	Update and send to Anti-Coagulation Committee; ADTC to approve virtually when updated. Email to author: KH/RM	KH / RM KW 02/02/2026
6.7	ADTC reviewed the Arthroplasty Analgesia Pathway, within the updated Enhanced Recovery After Surgery (ERAS) for elective hip and knee arthroplasty, and Patient Info Leaflet. Adapted from Lothian patient information leaflet describes patient pain control and prints out easily. ADTC requested that all brand names be taken out and that the leaflet should go to Patient Experience Team for approval first.	To be approved by Patient Exp Team Email to author: SS	KW 02/02/2026
7.	FOR INFORMATION and NOTING:		
7.1	ADTC reviewed the Clinical Documents Update – Right Decision Service – Drugs & Therapeutics. Pharmacy department is in the process of updating and uploading new documents, with removal of those no longer required. As RDS is updated, clinical documents are removed from the Medicines microsite. Working through document management with clinical governance to ensure documents are in the appropriate location. It was noted that a project manager would help to have project oversight and this has been discussed with service leads. ADTC agreed that this should be more formal arrangement.	ADTC Noted Letter from ADTC to Clinical Governance to request more formal arrangement.	MC 28/02/2026
7.2	ADTCC newsletter update - December 2025	ADTC Noted	MC
8.	FEEDBACK from SUBGROUPS		
8.1	Anticoagulation Committee (draft) minute – 1 st December 2025. Engagement in the committee is good, but timings of meetings make it difficult for all to attend; decision making virtually.	ADTC Noted	RM
8.2	Antimicrobial Management Team action tracker – 19 November 2025. Antimicrobial targets for primary care have been agreed for discussion with primary care leads. Request for robust data to allow review and highlight areas with practices. It was agreed that prescribing data and dashboard should be available in Power BI for measures to go out to practices and that Antimicrobial team should have sight of intention before sending to practices.	ADTC Noted Power BI report review	KMacl / EJ 16/03/2026
8.3	IV Therapy Group meeting (draft) minute – 12 November 2025	ADTC Noted	RM
8.4	Medicines Resource Group – next meeting January 2026	ADTC Noted	MC
8.5	Medicines Governance and Safety Group (draft) minute – 15 September 2025	ADTC Noted	RM

8.6	Tissue Viability Steering Group meeting (draft) minute – 11 December 2025	ADTC Noted	RM
8.7	East Region Formulary Committee minute from meeting held 12 November 2025	ADTC Noted	MC
8.8	NHS Lothian ADTC minute from meeting held 3 October 2025.	ADTC Noted	MC
9.	AOCB		
9.1	None		
Date and time of next meeting: Wednesday 25 FEBRUARY 2026 at 12:30pm via Microsoft Teams.			
Items expected for future Agendas –			